Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Tubular reabsorption and local production of urine hepcidin-25

Authors: Hilde PE Peters, Coby MM Laarakkers, Peter Pickkers, Rosalinde Masereeuw, Otto C Boerman, Annemarie Eek, Elisabeth AM Cornelissen, Dorine W Swinkels, Jack FM Wetzels

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Hepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients with renal insufficiency, which may contribute to anemia. Urine hepcidin was found to be increased in some patients after cardiac surgery, and these patients were less likely to develop acute kidney injury. It has been suggested that urine hepcidin may protect by attenuating heme-mediated injury, but processes involved in urine hepcidin excretion are unknown.

Methods

To assess the role of tubular reabsorption we compared fractional excretion (FE) of hepcidin-25 with FE of β2-microglobulin (β2m) in 30 patients with various degrees of tubular impairment due to chronic renal disease. To prove that hepcidin is reabsorbed by the tubules in a megalin-dependent manner, we measured urine hepcidin-1 in wild-type and kidney specific megalin-deficient mice. Lastly, we evaluated FE of hepcidin-25 and β2m in 19 patients who underwent cardiopulmonary bypass surgery. Hepcidin was measured by a mass spectrometry assay (MS), whereas β2m was measured by ELISA.

Results

In patients with chronic renal disease, FE of hepcidin-25 was strongly correlated with FE of β2m (r = 0.93, P <0.01). In megalin-deficient mice, urine hepcidin-1 was 7-fold increased compared to wild-type mice (p < 0.01) indicating that proximal tubular reabsorption occurs in a megalin- dependent manner. Following cardiac surgery, FE of hepcidin-25 increased despite a decline in FE of β2m, potentially indicating local production at 12–24 hours.

Conclusions

Hepcidin-25 is reabsorbed by the renal tubules and increased urine hepcidin-25 levels may reflect a reduction in tubular uptake. Uncoupling of FE of hepcidin-25 and β2m in cardiac surgery patients suggests local production.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ganz T: Molecular control of iron transport. J Am Soc Nephrol. 2007, 18: 394-400. 10.1681/ASN.2006070802.CrossRefPubMed Ganz T: Molecular control of iron transport. J Am Soc Nephrol. 2007, 18: 394-400. 10.1681/ASN.2006070802.CrossRefPubMed
2.
go back to reference Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW: Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011, 57: 1650-1669. 10.1373/clinchem.2009.140053.CrossRefPubMed Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW: Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011, 57: 1650-1669. 10.1373/clinchem.2009.140053.CrossRefPubMed
3.
go back to reference Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004, 306: 2090-2093. 10.1126/science.1104742.CrossRefPubMed Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004, 306: 2090-2093. 10.1126/science.1104742.CrossRefPubMed
4.
go back to reference Ramey G, Deschemin JC, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S: Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010, 95: 501-504. 10.3324/haematol.2009.014399.CrossRefPubMed Ramey G, Deschemin JC, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S: Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010, 95: 501-504. 10.3324/haematol.2009.014399.CrossRefPubMed
5.
go back to reference Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002, 110: 1037-1044.CrossRefPubMedPubMedCentral Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002, 110: 1037-1044.CrossRefPubMedPubMedCentral
6.
go back to reference Kemna E, Pickkers P, Nemeth E, der HH V, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005, 106: 1864-1866. 10.1182/blood-2005-03-1159.CrossRefPubMed Kemna E, Pickkers P, Nemeth E, der HH V, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005, 106: 1864-1866. 10.1182/blood-2005-03-1159.CrossRefPubMed
7.
go back to reference Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF: Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010, 25: 848-853. 10.1093/ndt/gfp546.CrossRefPubMed Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF: Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010, 25: 848-853. 10.1093/ndt/gfp546.CrossRefPubMed
8.
go back to reference Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009, 75: 976-981. 10.1038/ki.2009.21.CrossRefPubMed Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009, 75: 976-981. 10.1038/ki.2009.21.CrossRefPubMed
9.
go back to reference Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja H, Birmingham DJ, Yu CY, Hebert LA, Rovin BH: Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 2008, 74: 799-807. 10.1038/ki.2008.316.CrossRefPubMedPubMedCentral Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja H, Birmingham DJ, Yu CY, Hebert LA, Rovin BH: Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 2008, 74: 799-807. 10.1038/ki.2008.316.CrossRefPubMedPubMedCentral
10.
go back to reference Ho J, Lucy M, Krokhin O, Hayglass K, Pascoe E, Darroch G, Rush D, Nickerson P, Rigatto C, Reslerova M: Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case–control study. Am J Kidney Dis. 2009, 53: 584-595. 10.1053/j.ajkd.2008.10.037.CrossRefPubMed Ho J, Lucy M, Krokhin O, Hayglass K, Pascoe E, Darroch G, Rush D, Nickerson P, Rigatto C, Reslerova M: Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case–control study. Am J Kidney Dis. 2009, 53: 584-595. 10.1053/j.ajkd.2008.10.037.CrossRefPubMed
11.
go back to reference Ho J, Reslerova M, Gali B, Gao A, Bestland J, Rush DN, Nickerson PW, Rigatto C: Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol. 2011, 6: 2340-2346. 10.2215/CJN.01000211.CrossRefPubMedPubMedCentral Ho J, Reslerova M, Gali B, Gao A, Bestland J, Rush DN, Nickerson PW, Rigatto C: Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol. 2011, 6: 2340-2346. 10.2215/CJN.01000211.CrossRefPubMedPubMedCentral
12.
go back to reference Haase-Fielitz A, Mertens PR, Plass M, Kuppe H, Hetzer R, Westerman M, Ostland V, Prowle JR, Bellomo R, Haase M: Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury - an observational cohort study. Crit Care. 2011, 15: R186-10.1186/cc10339.CrossRefPubMedPubMedCentral Haase-Fielitz A, Mertens PR, Plass M, Kuppe H, Hetzer R, Westerman M, Ostland V, Prowle JR, Bellomo R, Haase M: Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury - an observational cohort study. Crit Care. 2011, 15: R186-10.1186/cc10339.CrossRefPubMedPubMedCentral
13.
go back to reference Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, Swinkels DW: (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem. 2009, 389: 124-129. 10.1016/j.ab.2009.03.039.CrossRefPubMed Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, Swinkels DW: (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem. 2009, 389: 124-129. 10.1016/j.ab.2009.03.039.CrossRefPubMed
14.
go back to reference Zhang X, Rovin BH: Hepcidin expression by human monocytes in response to adhesion and pro-inflammatory cytokines. Biochim Biophys Acta. 2010, 1800: 1262-1267. 10.1016/j.bbagen.2010.08.005.CrossRefPubMedPubMedCentral Zhang X, Rovin BH: Hepcidin expression by human monocytes in response to adhesion and pro-inflammatory cytokines. Biochim Biophys Acta. 2010, 1800: 1262-1267. 10.1016/j.bbagen.2010.08.005.CrossRefPubMedPubMedCentral
15.
go back to reference Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE: Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol. 1999, 155: 1361-1370. 10.1016/S0002-9440(10)65238-8.CrossRefPubMedPubMedCentral Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE: Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol. 1999, 155: 1361-1370. 10.1016/S0002-9440(10)65238-8.CrossRefPubMedPubMedCentral
16.
go back to reference Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HP, van Dongen-Lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW: Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010, 56: 1570-1579. 10.1373/clinchem.2010.149187.CrossRefPubMed Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HP, van Dongen-Lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW: Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010, 56: 1570-1579. 10.1373/clinchem.2010.149187.CrossRefPubMed
17.
go back to reference Tjalsma H, Laarakkers CM, van Swelm RP, Theurl M, Theurl I, Kemna EH, van der Burgt YE, Venselaar H, Dutilh BE, Russel FG, Weiss G, Masereeuw R, Fleming RE, Swinkels DW: Mass spectrometry analysis of hepcidin peptides in experimental mouse models. PLoS One. 2011, 6: e16762-10.1371/journal.pone.0016762.CrossRefPubMedPubMedCentral Tjalsma H, Laarakkers CM, van Swelm RP, Theurl M, Theurl I, Kemna EH, van der Burgt YE, Venselaar H, Dutilh BE, Russel FG, Weiss G, Masereeuw R, Fleming RE, Swinkels DW: Mass spectrometry analysis of hepcidin peptides in experimental mouse models. PLoS One. 2011, 6: e16762-10.1371/journal.pone.0016762.CrossRefPubMedPubMedCentral
18.
go back to reference Levey AS, Greene T, Kusek JW, Becj GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000, 11: 0828- Levey AS, Greene T, Kusek JW, Becj GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000, 11: 0828-
19.
go back to reference Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL: New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009, 20: 629-637. 10.1681/ASN.2008030287.CrossRefPubMedPubMedCentral Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL: New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009, 20: 629-637. 10.1681/ASN.2008030287.CrossRefPubMedPubMedCentral
20.
go back to reference Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood. 2008, 112: 4292-4297. 10.1182/blood-2008-02-139915.CrossRefPubMed Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood. 2008, 112: 4292-4297. 10.1182/blood-2008-02-139915.CrossRefPubMed
21.
go back to reference Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One. 2008, 3: e2706-10.1371/journal.pone.0002706.CrossRefPubMedPubMedCentral Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One. 2008, 3: e2706-10.1371/journal.pone.0002706.CrossRefPubMedPubMedCentral
22.
go back to reference Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001, 276: 7811-7819. 10.1074/jbc.M008923200.CrossRefPubMed Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001, 276: 7811-7819. 10.1074/jbc.M008923200.CrossRefPubMed
23.
go back to reference Lou DQ, Nicolas G, Lesbordes JC, Viatte L, Grimber G, Szajnert MF, Kahn A, Vaulont S: Functional differences between hepcidin 1 and 2 in transgenic mice. Blood. 2004, 103: 2816-2821. 10.1182/blood-2003-07-2524.CrossRefPubMed Lou DQ, Nicolas G, Lesbordes JC, Viatte L, Grimber G, Szajnert MF, Kahn A, Vaulont S: Functional differences between hepcidin 1 and 2 in transgenic mice. Blood. 2004, 103: 2816-2821. 10.1182/blood-2003-07-2524.CrossRefPubMed
24.
go back to reference Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W: The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol. 2005, 184: 361-370. 10.1677/joe.1.05729.CrossRefPubMed Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W: The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol. 2005, 184: 361-370. 10.1677/joe.1.05729.CrossRefPubMed
25.
go back to reference Prowle JR, Ostland V, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Bagshaw SM, Haase-Fielitz A, Haase M, Westerman M, Bellomo R: Greater increase in urinary hepcidin predicts protection from acute kidney injury after cardiopulmonary bypass. Nephrol Dial Transplant. 2012, 27: 595-602. 10.1093/ndt/gfr387.CrossRefPubMed Prowle JR, Ostland V, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Bagshaw SM, Haase-Fielitz A, Haase M, Westerman M, Bellomo R: Greater increase in urinary hepcidin predicts protection from acute kidney injury after cardiopulmonary bypass. Nephrol Dial Transplant. 2012, 27: 595-602. 10.1093/ndt/gfr387.CrossRefPubMed
26.
go back to reference Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Mockel M, Matalanis G, Dragun D, Haase-Fielitz A: Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009, 88: 124-130. 10.1016/j.athoracsur.2009.04.023.CrossRefPubMed Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Mockel M, Matalanis G, Dragun D, Haase-Fielitz A: Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009, 88: 124-130. 10.1016/j.athoracsur.2009.04.023.CrossRefPubMed
27.
go back to reference Farnaud S, Rapisarda C, Bui T, Drake A, Cammack R, Evans RW: Identification of an iron-hepcidin complex. Biochem J. 2008, 413: 553-557. 10.1042/BJ20080406.CrossRefPubMed Farnaud S, Rapisarda C, Bui T, Drake A, Cammack R, Evans RW: Identification of an iron-hepcidin complex. Biochem J. 2008, 413: 553-557. 10.1042/BJ20080406.CrossRefPubMed
28.
go back to reference Gerardi G, Biasiotto G, Santambrogio P, Zanella I, Ingrassia R, Corrado M, Cavadini P, Derosas M, Levi S, Arosio P: Recombinant human hepcidin expressed in Escherichia coli isolates as an iron containing protein. Blood Cells Mol Dis. 2005, 35: 177-181. 10.1016/j.bcmd.2005.06.002.CrossRefPubMed Gerardi G, Biasiotto G, Santambrogio P, Zanella I, Ingrassia R, Corrado M, Cavadini P, Derosas M, Levi S, Arosio P: Recombinant human hepcidin expressed in Escherichia coli isolates as an iron containing protein. Blood Cells Mol Dis. 2005, 35: 177-181. 10.1016/j.bcmd.2005.06.002.CrossRefPubMed
Metadata
Title
Tubular reabsorption and local production of urine hepcidin-25
Authors
Hilde PE Peters
Coby MM Laarakkers
Peter Pickkers
Rosalinde Masereeuw
Otto C Boerman
Annemarie Eek
Elisabeth AM Cornelissen
Dorine W Swinkels
Jack FM Wetzels
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-70

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.